BiotechTube
Home/Calico/Philip Kym, Ph.D.
PK

Philip Kym, Ph.D.

Head of Drug Discovery

Calico

Therapeutic Areas

AgingPolycystic Kidney DiseaseVanishing White Matter DiseaseAge-related Diseases

Calico Pipeline

DrugIndicationPhase
Fosigotifator (ABBV-CLS-7262)Vanishing White Matter DiseasePhase 2
Undisclosed ProgramAutosomal Dominant Polycystic Kidney Disease (ADPKD)Phase 2

Leadership Team at Calico

AD
Arthur D. Levinson, Ph.D.
Founder & CEO
JR
Joseph R. Arron, M.D., Ph.D.
Head of Human Biology and Genetics
View full Calico profile